Spark Therapeutics reports $28.7 million net loss for second quarter

Spark Therapeutics reported a $28.7 million net loss applicable to common stockholders for the second quarter compared with a net loss applicable to common stockholders of $14.3 million in the second quarter of 2015, according to a press release.Basic and diluted net loss per common share was $1.04 compared with basic and diluted net loss per common share of $0.60 a year ago.